Promising Activity of Patritumab Deruxtecan in Patients with HR-positive, HER2-negative MBC Who Progressed on CDK4/6 Inhibitors By Ogkologos - September 23, 2025 325 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ICARUS-BREAST01 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR The Horror Story Of What Can Happen When You Don’t Pay... September 16, 2019 Dexrazoxane Protects the Heart Long Term for Kids Being Treated for... March 16, 2023 ΚΑΡΚΙΝΟΣ ΤΟΥ ΠΡΟΣΤΑΤΗ November 24, 2018 Breathing Amidst Uncertainty March 5, 2021 Load more HOT NEWS Erdafitinib Prolongs Survival in Patients with Metastatic Urothelial Carcinoma and FGFR... Neoadjuvant Oxaliplatin-Fluoropyrimidine Chemotherapy Can Be Delivered Safely in Patients with Operable... The Evidence Is In: COVID Vaccines Do Protect Patients With Cancer... Helping Dogs—and Humans—with Cancer: NCI’s Comparative Oncology Studies
